Cyclophosphamide versus placebo in scleroderma lung disease

Authors :: Tashkin, Donald P.; Elashoff, Robert; Clements, Philip J.; Goldin, Jonathan; Roth, Michael D.; Furst, Daniel E.
Arriola, Edgar; Silver, Richard; Strange, Charlie; Bolster, Marcy; Seibold, James R.
Riley, David J.; Hsu, Vivien M.; Varga, John; Schraufnagel, Dean E.
Theodore, Arthur; Simms, Robert; Wise, Robert; Wigley, Fredrick; White, Barbara; Steen, Virginia; Read, Charles; Mayes, Maureen; Parsley, Ed D.O.; Mubarak, Kamal
Connolly, Kari; Golden, Jeffrey; Olman, Mitchell; Fessler, Barri; Rothfield, Naomi; Metersky, Mark
Source :: The New England Journal of Medicine. June 22, 2006, Vol. 354 Issue 25, p2655, 12 p.
Publication Year :: 2006
Abstract: A double-blind, randomized, placebo-controlled trial was conducted to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidence of active alveolitis and scleroderma-related interstitial lung disease. It was found that one year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life.

Subjects :: Scleroderma (Disease) -- Drug therapy
Systemic scleroderma -- Drug therapy
Lung diseases -- Drug therapy
Quality of life

Tools